CUMYL-NBMINACA (SGT-152, Cumyl-BC[2.2.1]HpMINACA) is a synthetic cannabinoid compound first reported in a 2013 patent,[1] but not identified as a designer drug until 2021, being identified by a forensic laboratory in Germany in February 2021.[2][3]

CUMYL-NBMINACA
Identifiers
  • [1-(bicyclo[2.2.1]heptan-2-yl)methyl]-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC25H29N3O
Molar mass387.527 g·mol−1
3D model (JSmol)
  • CC(C)(C1=CC=CC=C1)NC(=O)C2=NN(C3=CC=CC=C32)CC4CC5CCC4C5
  • InChI=1S/C25H29N3O/c1-25(2,20-8-4-3-5-9-20)26-24(29)23-21-10-6-7-11-22(21)28(27-23)16-19-15-17-12-13-18(19)14-17/h3-11,17-19H,12-16H2,1-2H3,(H,26,29)
  • Key:MLRLLZWQYJJPEX-UHFFFAOYSA-N

See also

edit

References

edit
  1. ^ WO 2014167530, Bowden MJ, Williamson PB, "Cannabinoid compounds", issued 11 April 2013 
  2. ^ Pulver B, Riedel J, Schönberger T, Pütz M, Schäper J, Kunert N, et al. (December 2021). "Comprehensive structural characterisation of the newly emerged synthetic cannabimimetics Cumyl-BC [2.2. 1] HpMeGaClone, Cumyl-BC [2.2. 1] HpMINACA, and Cumyl-BC [2.2. 1] HpMICA featuring a norbornyl methyl side chain". Forensic Chemistry. 26: 100371. doi:10.1016/j.forc.2021.100371. S2CID 243179410.
  3. ^ "New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU Early Warning System" (PDF). June 2022.